BBCMF (Lir Life Sciences) Forward PE Ratio: 0.00 (As of Jul. 02, 2026)


BBCMF Lir Life Sciences Corp BBCMF
15 GF Score
Price $0.05
View Full Analysis

What is Lir Life Sciences Forward PE Ratio?

Lir Life Sciences BBCMF 15 Forward PE Ratio is 0.00 as of Jul. 02, 2026. GuruFocus rates BBCMF with a GF Score™ of 15/100. Among 355 Biotechnology companies, Lir Life Sciences ranks worse than 281689.86% on this metric.

Lir Life Sciences's Forward PE Ratio for today is 0.00.

Lir Life Sciences's PE Ratio without NRI for today is 0.00.

Lir Life Sciences's PE Ratio (TTM) for today is 0.00.

Lir Life Sciences  (OTCPK:BBCMF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Lir Life Sciences Forward PE Ratio Related Terms

Lir Life Sciences Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for Lir Life Sciences's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lir Life Sciences Forward PE Ratio Chart

Lir Life Sciences Annual Data
Trend
Forward PE Ratio

Lir Life Sciences Quarterly Data
Forward PE Ratio

BBCMF vs VRTX, REGN, ALNY: Forward PE Ratio Comparison

For the Biotechnology subindustry, Lir Life Sciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lir Life Sciences Forward PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lir Life Sciences's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Lir Life Sciences's Forward PE Ratio falls into.


BBCMF
15GF Score
Lir Life Sciences Corp BBCMF
Forward PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lir Life Sciences Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 0.00 mean?
Lir Life Sciences (BBCMF) has a Forward PE Ratio of 0.00 as of Jul. 02, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Lir Life Sciences and its competitors. According to the industry distribution chart, Lir Life Sciences ranks #999999 out of 355 companies in the Biotechnology industry.
Is Lir Life Sciences' Forward PE Ratio too high?
Lir Life Sciences' current Forward PE Ratio is 0.00. Based on the distribution chart, Lir Life Sciences ranks #999999 out of 355 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lir Life Sciences has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Lir Life Sciences' Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lir Life Sciences ranks #999999 out of 355 companies for Forward PE Ratio. This places Lir Life Sciences in the lower half of its industry. The industry median Forward PE Ratio is 22.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.44, based on 355 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Lir Life Sciences and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lir Life Sciences's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lir Life Sciences stock overvalued right now?
Lir Life Sciences (BBCMF) has a current Forward PE Ratio of 0.00. The current Forward PE Ratio is 0.00. Lir Life Sciences' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Lir Life Sciences (BBCMF), the current Forward PE Ratio is 0.00 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lir Life Sciences Business Description

Other Exchanges N790:GermanySKNY:Canada
Address 505-1505 West 2nd Avenue, Vancouver, BC, CAN, V6J 1H2
Lir Life Sciences Corp is a biotechnology company developing transdermal and sublingual drug-delivery technologies for GLP-1-based obesity therapies, with the focus of improving accessibility and patient experience.
15GF Score

Get the complete analysis for BBCMF

Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.05
Price